Valuation: Labcorp Holdings Inc.

Market Cap 21.84B 19.15B 17.65B 16.53B 30.99B 2,060B 31.63B 212B 82.09B 1,018B 82.01B 80.22B 3,531B P/E 2026 *
18.5x
P/E 2027 * 17.2x
Enterprise Value 26.47B 23.21B 21.4B 20.03B 37.56B 2,497B 38.34B 257B 99.51B 1,234B 99.41B 97.24B 4,280B EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.67x
Free-Float
99.65%
Yield 2026 *
1.09%
Yield 2027 * 1.1%
1 day+1.93%
1 week+6.70%
Current month+4.39%
1 month+5.04%
3 months+1.15%
6 months+6.92%
Current year+8.21%
1 week 253.05
Extreme 253.05
272.34
1 month 253.05
Extreme 253.05
275
Current year 245
Extreme 245
292.02
1 year 241.81
Extreme 241.81
293.72
3 years 191.97
Extreme 191.97
293.72
5 years 191.97
Extreme 191.97
317.17
10 years 98.02
Extreme 98.02
317.17
Date Insider Type Main position Quantity % Market Cap.
06-07Sell

General Counsel

-762 0.0009%
05-10Sell

Chief Executive Officer

-5,903 0.0072%
03-25Free

General Counsel

2,035 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
+1.93%+6.70%+5.64%+14.94% 21.84B
+0.45%+14.47%+55.74%+425.40% 37.34B
-0.78%+2.92%-21.91%-41.22% 7.04B
+1.22%+8.93%+4.63%+85.41% 4.72B
+1.76%+1.58%+22.09%+60.13% 2.99B
+1.67%+25.98%-22.07%+1,097.60% 2.04B
-4.74%+3.56%+29.74%-27.79% 1.78B
+3.20%+26.52%+97.91%-12.69% 1.79B
-6.73%-9.88%-22.08%-69.93% 1.62B
+2.63%+4.55%+21.57%-1.01% 1.62B
Average +0.18%+6.23%+17.13%+153.08% 8.28B
Weighted average by Cap. +1.24%+8.46%+28.04%+224.15%

Financials

2026 *2027 *
Net sales 14.76B 12.94B 11.93B 11.17B 20.94B 1,392B 21.37B 143B 55.47B 688B 55.42B 54.21B 2,386B 15.42B 13.52B 12.46B 11.67B 21.88B 1,455B 22.33B 150B 57.96B 719B 57.9B 56.63B 2,493B
Net income 1.18B 1.04B 956M 895M 1.68B 112B 1.71B 11.48B 4.44B 55.12B 4.44B 4.34B 191B 1.23B 1.08B 997M 934M 1.75B 116B 1.79B 11.99B 4.64B 57.54B 4.63B 4.53B 200B
Net Debt 4.63B 4.06B 3.75B 3.51B 6.57B 437B 6.71B 45.02B 17.42B 216B 17.4B 17.02B 749B 3.94B 3.46B 3.19B 2.98B 5.59B 372B 5.71B 38.3B 14.82B 184B 14.81B 14.48B 637B
Logo Labcorp Holdings Inc.
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Employees
66,385
Date Price Change Volume
26-06-26 US$271.47 +1.93% 1,021,442
26-06-25 US$266.34 +0.44% 582,307
26-06-24 US$265.18 +2.55% 632,765
26-06-23 US$258.59 +1.64% 414,725
26-06-22 US$254.43 -0.54% 784,900
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
266.34USD
Average target price
310.12USD
Spread / Average Target
+16.44%

Quarterly revenue - Rate of surprise